Tumor Cell Overview

Compound Osimertinib

Area under investigation

EGFRm NSCLC

Scientific Pillar Tumor Drivers & Resistance Mechanisms

Compound Capivasertib

Area under investigation

HR-positive/HER2-negative breast cancer, mCRPC, mHSPC

Scientific Pillar Tumor Drivers & Resistance Mechanisms

Compound Camizestrant

Area under investigation

Advanced solid tumors, HR-positive/HER2-negative breast cancer

Scientific Pillar Tumor Drivers & Resistance Mechanisms

Compound AZD9829

Area under investigation

AML/MDS

Scientific Pillar Antibody-Drug Conjugates

Compound Fam-trastuzumab deruxtecan-nxki (DS-8201a; in collaboration with Daiichi Sankyo, Inc., Basking Ridge, NJ, US)

Area under investigation

Advanced solid tumors, Gastric/GEJ cancer, HER2-positive breast cancer, HER2-low breast cancer, NSCLC, TNBC, BTCs, Urothelial carcinoma

Scientific Pillar Antibody-Drug Conjugates

Compound Savolitinib

Area under investigation

Advanced solid tumors, EGFRm NSCLC, Gastric cancer, MET-driven NSCLC, RCC

Scientific Pillar Tumor Drivers & Resistance Mechanisms

Compound Datopotamab deruxtecan (in collaboration with Daiichi Sankyo, Inc., Basking Ridge, NJ, US)

Area under investigation

Advanced solid tumors, Colorectal cancer, Gastric cancer, HER2-low breast cancer, HR-positive/HER2-negative breast cancer, mCRPC, NSCLC, Ovarian cancer, TNBC, Urothelial carcinoma, BTCs, Cervical cancer, Endometrial cancer, SCLC

Scientific Pillar Antibody-Drug Conjugates